Latest Gene Therapy News

Cryosite Limited reports a strong start to FY26 with a 22% revenue increase and a strategic warehouse acquisition that doubles capacity, positioning the company for sustained growth in clinical trial logistics.

Pathkey.AI has upgraded its TrialKey platform to include drug-level molecular and pharmacokinetic features, enhancing clinical trial predictions and opening doors to AI-driven drug discovery.

Cryosite Limited reported a 12% increase in revenue for FY25, driven by a 58% surge in its ultra-frozen and cryogenic segment, while deferring dividends to fund expansion plans.

CSL Limited posted a 14% rise in net profit for FY2025, underpinned by strong immunoglobulin sales and new product launches, while announcing plans to demerge its vaccines business, CSL Seqirus, to sharpen strategic focus.

Vitrafy Life Sciences reported a $32.7 million loss for FY25, driven by investments in its next-generation cryopreservation platform following a $35 million IPO and a $4.8 million government grant. The company is progressing commercialization efforts with key partnerships in human and animal health.

Vitrafy Life Sciences reported robust progress in Q4 FY2025, advancing its cryopreservation technology and commercial partnerships while preparing for a pivotal product launch in FY2026.

NeuroScientific Biopharmaceuticals has appointed Nathan Smith as CEO, leveraging his deep cell therapy expertise to accelerate clinical development and commercialisation of its StemSmart technology.

CSL Limited posted a robust half-year performance with NPATA rising 5% at constant currency, driven by strong growth in CSL Behring and CSL Vifor despite challenges in its influenza vaccine segment. The company reaffirmed its FY25 guidance, anticipating double-digit earnings growth.

CSL Limited reported a solid 5% revenue increase and 6% rise in net profit after tax for the half year ended December 2024, underpinned by robust performance in its plasma therapies business despite headwinds in its influenza vaccine segment.

Vitrafy Life Sciences reported a dramatic increase in half-year losses to $25.7 million, yet successfully raised $35 million through an IPO to fuel its cryopreservation technology expansion.

PYC Therapeutics has secured Safety Review Committee approval to escalate dosing in its clinical trial for Autosomal Dominant Optic Atrophy, marking a pivotal step in developing a treatment for this currently untreatable blinding disease.

Vitrafy Life Sciences reports strong Q2 FY2025 progress, marked by a successful $35 million IPO, promising validation results in animal and human health, and strategic expansion into North America.